

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: NDA 20845

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

NDA 20-845

DEC 23 1999

INO Therapeutics, Inc.
Attention: Richard N. Williams, Ph.D.
54 Old Highway 22
Clinton, NJ 08809

Dear Dr. Williams:

Please refer to your new drug application (NDA) dated June 16, 1997, withdrawn on September 17, 1997 and resubmitted on May 26, 1999, under section 505(b) of the Federal Food, Drug, and Cosmetic Act for INOmax (nitric oxide) 100 and 800 ppm for Inhalation.

We acknowledge receipt of your submissions dated December 8, 1999 (two).

This new drug application provides for the use of INOmax (nitric oxide) 100 and 800 ppm for Inhalation, in conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (> 34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted, immediate container and carton labels included in your December 8, 1999 submission). Accordingly, the application is approved effective on the date of this letter.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We note that you have fulfilled the pediatric study requirement at this time.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 20-845
Page 2

If you have any questions, please contact:

Ms. Zelda McDonald
Regulatory Project Manager
(301) 594-5333

Sincerely yours

/S/

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20845

APPROVABLE LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Lowen

Public Health Service

Food and Drug Administration
Rockville MD 20857

NOV 19 1999

NDA 20-845

INO Therapeutics, Inc.
Attention: Richard N. Williams, Ph.D.
54 Old Highway 22
Clinton NJ 08809

Dear Dr. Williams:

Please refer to your new drug application (NDA) dated June 16, 1997, withdrawn on September 17, 1997 and resubmitted on May 26, 1999 under section 505(b) of the Federal Food, Drug, and Cosmetic Act for INOmax (nitric oxide) 100 and 800 ppm for Inhalation.

We note you submitted manufacturing and controls information, dated February 26, 1997. We also acknowledge receipt of your submissions dated June 10, 17 and 27, July 11 and 31, August 15, 18, 22 (two) and 28 (three), and September 8, 12 (three) and 16 (four), 1997; March 30, April 1 and December 15, 1998; June 1 and 4, August 13, September 27, and November 6, 1999.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to submit final printed labeling (FPL) for the drug. The package insert should be identical in content to the enclosed marked-up draft. The immediate container and carton labeling should be identical to the submitted draft (immediate container and carton labels submitted November 6, 1999), except that the storage statement should be changed to the following:

Store at 25° C (77° F) with excursions permitted between 15-30° C (59-86° F) [see USP Controlled Room Temperature].

This storage statement should be included on all labeling (package insert, and immediate container and carton labels).

The expiration date for drug product stored at 25° C will be 30 months.

Please submit 20 copies of the final printed labeling ten of which are individually mounted on heavy weight paper or similar material.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.